Board

Dr. Kenneth Macleod

Dr Kenneth Macleod is a Partner at Rosetta Capital, a venture capital firm focussed on the life sciences and medical devices . Ken has over 35 years’ experience in the life sciences sector in a career combining senior operating roles in healthcare companies (Abbott Labs., Serono SA) and life science fund management (SV Health Investors, …

Dr. Kenneth Macleod Read More »

Tassos Konstantinou Director

Tassos is an investment manager at IP Group and specializes in early stage investing in the life science sector. Before joining IP Group, Tassos was a business development executive at CRUK Commercial Partnerships (formerly CRT) where he led the intellectual property sourcing, licensing, and spin-out creation of CRUK-funded technologies. He has experience in technology transfer …

Tassos Konstantinou Director Read More »

Dr. Dmitrij Hristodorov Director

Dmitrij Hristodorov, PhD, is Partner at Forbion where, as a core member of the investment team, he contributes to investments across various stages, treatment modalities and diseases. Previously, he was Senior Director of Global Business Development & Licensing at Bayer Pharma, where he was responsible for ophthalmology, cardiology, nephrology, and pulmonology. Dmitrij currently serves as …

Dr. Dmitrij Hristodorov Director Read More »

Christina Takke Director

Christina is co-founder and Managing Director of V-Bio Ventures. With more than 20 years of investment experience in European venture capital, Christina was previously a partner with Forbion Capital Partners (formerly ABN AMRO Capital) where she led and managed a series of successful biotech investments since 2001. Christina currently serves on the boards of Confo …

Christina Takke Director Read More »

Dr. Rafiq Hasan Director

Rafiq is the CEO of Complement Therapeutics, a life sciences company aiming to develop the next generation of complement medicines. Rafiq has pursued a successful career in the pharmaceutical industry globally, including senior positions in ophthalmology with Bayer and Novartis. Most recently as Senior Vice President and Global Head of Ophthalmology at Bayer, Rafiq grew …

Dr. Rafiq Hasan Director Read More »

David Fellows Chair

David is Chair of Oxular and has more than 30 years of experience in various leadership roles within the ophthalmic pharmaceutical industry. He was previously CEO of Nightstar Therapeutics, a private biopharmaceutical company specialising in developing ocular gene therapies for patients with inherited retinal dystrophies, with David leading the company through a successful NASDAQ listing …

David Fellows Chair Read More »

Scroll to Top